Pfizer Rating Reiterated by TheStreet (PFE)
Pfizer (NYSE:PFE)‘s stock had its “buy” rating reiterated by research analysts at TheStreet in a report released on Tuesday, American Banking & Market News reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
In other Pfizer news, EVP Frank Damelio sold 131,810 shares of Pfizer stock on the open market in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $30.82, for a total transaction of $4,062,384.20. Following the transaction, the executive vice president now directly owns 356,451 shares in the company, valued at approximately $10,985,820. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Pfizer (NYSE:PFE) traded down 0.83% during mid-day trading on Tuesday, hitting $31.01. 25,016,416 shares of the company’s stock traded hands. Pfizer has a 52-week low of $26.76 and a 52-week high of $32.50. The stock has a 50-day moving average of $30.77 and a 200-day moving average of $29.85. The company has a market cap of $201.0 billion and a price-to-earnings ratio of 8.63.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, March 4th. Investors of record on Friday, February 7th will be paid a dividend of 0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Wednesday, February 5th. This is an increase from Pfizer’s previous quarterly dividend of $0.24.
A number of other analysts have also recently weighed in on PFE. Analysts at Cowen and Company downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note to investors on Friday, January 10th. They now have a $34.00 price target on the stock. Separately, analysts at UBS AG downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note to investors on Thursday, January 9th. Finally, analysts at Jefferies Group raised their price target on shares of Pfizer from $31.00 to $33.00 in a research note to investors on Thursday, January 9th. They now have a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $31.78.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.